Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
NeuroSense Therapeutics Ltd. (NRSN)
USD0.72
-0.01 (-1.52%)
IL NASDAQ Healthcare Biotechnology
Address
Building B 4672562
Herzliya, IL
Herzliya, IL
CEO
Alon Ben-Noon
Website
neurosense-tx.com
IPO
2021-12-09
CIK 1875091 ISIN IL0011809592
Also trades on
NASDAQ Capital Market · NRSN (USD)
NASDAQ Capital Market · NRSNW (USD)
Description
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.72
-0.01 (-1.52%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
165.7K
Beta
1.54
Float Shares
16.11M
Free Float %
65.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.49% | -4.49% | +0.05% | -9.63% | -30.97% | +6.81% | -51.40% | -47.35% | -79.67% | -79.67% | -79.67% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
0.72
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-89.92
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+20.0% Q4'25: -56.3% (vs Q4'24)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q4'25: +821.7% (vs Q4'24)
-
Share dilution Biotechnology: -3.4%+37.0% Q4'25: +18.0% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q4'25: -0.01× (vs Q4'24)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
714.1K
714.0K – 714.1K
|
3.28M
3.28M – 3.28M
+359.0% YoY
|
13.38M
13.38M – 13.38M
+308.0% YoY
|
360.21M
360.21M – 360.21M
+2,593.1% YoY
|
774.73M
774.73M – 774.73M
+115.1% YoY
|
| EBITDA |
-9.88M
|
-11.11M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-9.90M
|
-11.13M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-10.21M
est: -12.09M (+15.6%)
|
-11.13M
est: -8.78M (-26.7%)
|
-10.56M
-10.98M – -10.15M
-20.4% YoY
|
-15.16M
-15.16M – -15.16M
-43.5% YoY
|
-6.73M
-6.73M – -6.73M
+55.6% YoY
|
42.04M
42.04M – 42.04M
+724.3% YoY
|
169.71M
169.71M – 169.71M
+303.6% YoY
|
| SGA |
4.20M
|
4.86M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.55
est: -0.65 (+15.4%)
|
-0.44
est: -0.35 (-25.8%)
|
-0.42
-0.43 – -0.40
-20.1% YoY
|
-0.60
-0.60 – -0.60
-41.7% YoY
|
-0.26
-0.26 – -0.26
+55.6% YoY
|
1.65
1.65 – 1.65
+724.3% YoY
|
6.66
6.66 – 6.66
+303.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
13
Total invested
286.7K
Insider transactions (90d)
0
Beneficial owners (>5%)
7
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Alon Ben-Noon | 3.00M | 27.42% | 3.00M | — | 3.00M | — | IN | Israel | 2021-12-23 | ↗ |
| 2 | Abir Raveh | 2.30M | 9.99% | — | 2.30M | — | 2.30M | IN, OO | Israel | 2024-12-09 | ↗ |
| 3 | Goldfinger Trust | 2.30M | 9.99% | — | 2.30M | — | 2.30M | OO | Israel | 2024-12-09 | ↗ |
| 4 | Rimon Gold Assets Ltd. | 2.30M | 9.99% | — | 2.30M | — | 2.30M | CO | Israel | 2024-12-09 | ↗ |
| 5 | Gordon. | 1.04M | 9.48% | 1.04M | — | 1.04M | — | IN | Israel | 2021-12-20 | ↗ |
| 6 | E Europe Limited | 602.5K | 5.51% | 602.5K | — | 602.5K | — | CO | Gibraltar | 2021-12-30 | ↗ |
| 7 | Real Property International Limited | 452.5K | 3.84% | 452.5K | — | 452.5K | — | CO | British Virgin Islands | 2023-03-15 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
13
+0 vs prev Q
New positions
3
Closed positions
3
Increased
4
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | YORKVILLE ADVISORS GLOBAL, LP | 100.0K +100.0K (+100.0%) | 76.9K +76.9K (+100.0%) | 0.39% +0.394 pp | 0.05% +0.048 pp | USD0.77 +0.0% | 3 qtrs — |
| 2 | TWO SIGMA INVESTMENTS, LP | 51.5K +30.5K (+144.5%) | 39.6K +13.3K (+50.4%) | 0.20% +0.120 pp | 0.00% +0.000 pp | USD0.97 -20.6% | 2 qtrs — |
| 3 | MEITAV INVESTMENT HOUSE LTD | 40.0K +— (+0.0%) | 30.8K -19.2K (-38.5%) | 0.16% +0.000 pp | 0.00% 0.000 pp | USD1.72 -55.2% | 12 qtrs — |
| 4 | GTS SECURITIES LLC | 35.8K +35.8K (+100.0%) | 27.5K +27.5K (+100.0%) | 0.14% +0.141 pp | 0.00% +0.001 pp | USD0.77 +0.0% | 1 qtrs NEW |
| 5 | UBS GROUP AG | 30.9K +16.2K (+110.6%) | 23.7K +5.4K (+29.6%) | 0.12% +0.064 pp | 0.00% +0.000 pp | USD0.98 -21.4% | 4 qtrs — |
| 6 | COMMONWEALTH EQUITY SERVICES, LLC | 22.8K +1.7K (+8.0%) | 17.5K -8.5K (-32.6%) | 0.09% +0.007 pp | 0.00% +0.000 pp | USD1.31 -41.2% | 6 qtrs — |
| 7 | SQUAREPOINT OPS LLC | 17.9K -77.4K (-81.2%) | 13.8K -105.4K (-88.4%) | 0.07% -0.305 pp | 0.00% 0.000 pp | USD1.58 -51.3% | 3 qtrs — |
| 8 | PATHSTONE HOLDINGS, LLC | 16.5K +16.5K (+100.0%) | 12.7K +12.7K (+100.0%) | 0.07% +0.065 pp | 0.00% +0.000 pp | USD0.77 +0.0% | 1 qtrs NEW |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 15.9K +— (+0.0%) | 12.2K -7.6K (-38.5%) | 0.06% +0.000 pp | 0.00% +0.000 pp | USD0.89 -13.5% | 9 qtrs — |
| 10 | CREATIVE PLANNING | 11.9K +11.9K (+100.0%) | 9.2K +9.2K (+100.0%) | 0.05% +0.047 pp | 0.00% +0.000 pp | USD0.77 +0.0% | 1 qtrs NEW |
| 11 | SBI SECURITIES CO., LTD. | 1.5K +— (+0.0%) | 1.1K -700.0 (-38.5%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.86 -58.6% | 5 qtrs — |
| 12 | JONES FINANCIAL COMPANIES LLLP | 1.0K +— (+0.0%) | 769.00 -471.0 (-38.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.89 -59.3% | 3 qtrs — |
| 13 | JESSUP WEALTH MANAGEMENT, INC | 500.00 +500.0 (+100.0%) | 385.00 +385.0 (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD0.77 +0.0% | 1 qtrs NEW |
| 14 | MORGAN STANLEY | — -66.4K (-100.0%) | — -83.0K (-100.0%) | 0.00% -0.261 pp | 0.00% +0.000 pp | USD— | 9 qtrs SOLD |
| 15 | CWM, LLC | — -1.0K (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD— | 14 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-26 | Russek-Blum Niva | Officer | A-Award | A | Ordinary Shares | 200,000 | 0.00 | — | 467,953 | D | ↗ |
| 2026-03-26 | Eisenberg Or | Officer | A-Award | A | Ordinary Shares | 200,000 | 0.00 | — | 1,254,050 | D | ↗ |
| 2026-03-26 | Binder Hagit | Officer | A-Award | A | Ordinary Shares | 200,000 | 0.00 | — | 521,806 | D | ↗ |
| 2026-03-18 | Tracik Ferenc | Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 428,011 | D | ↗ |
| 2026-03-18 | Russek-Blum Niva | Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 39,881 | D | ↗ |
| 2026-03-18 | Pellizzari Christine A | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 48,000 | D | ↗ |
| 2026-03-18 | Mandil-Levin Revital | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 52,526 | D | ↗ |
| 2026-03-18 | Leuchtenberger Mark | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 75,000 | D | ↗ |
| 2026-03-18 | Golan Roy | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 60,000 | D | ↗ |
| 2026-03-18 | Eisenberg Or | Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 139,416 | D | ↗ |
| 2026-03-18 | Claiborne Cary J | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 48,000 | D | ↗ |
| 2026-03-18 | Binder Hagit | Officer | — | — | Restricted Share Units | 0 | 0.00 | — | 10,000 | D | ↗ |
| 2026-03-18 | Ben-Noon Alon | Officer / 10% Owner | — | — | Ordinary Shares | 0 | 0.00 | — | 360,777 | D | ↗ |
| 2024-12-05 | Ben-Noon Alon | Officer / 10% Owner | — | — | Warrants to purchase Ordinary Shares | 80,000 | 1.25 | 100.0K | 0 | D | ↗ |
| 2024-08-15 | Tracik Ferenc | Officer | — | — | Warrants to purchase Ordinary Shares | 66,667 | 0.75 | 50.0K | 0 | D | ↗ |
| 2024-08-15 | Eisenberg Or | Officer | — | — | Warrants to purchase Ordinary Shares | 66,666 | 0.75 | 50.0K | 0 | D | ↗ |
| 2024-08-15 | Ben-Noon Alon | Officer / 10% Owner | — | — | Warrants to purchase Ordinary Shares | 26,666 | 0.75 | 20.0K | 0 | D | ↗ |
| 2023-03-10 | Pellizzari Christine A | Director | — | — | Options to Purchase Ordinary Shares | 72,000 | 1.43 | 103.0K | 0 | D | ↗ |
| 2023-03-10 | Mandil-Levin Revital | Director | — | — | Options to Purchase Ordinary Shares | 72,000 | 1.43 | 103.0K | 0 | D | ↗ |
| 2023-03-10 | Claiborne Cary J | Director | — | — | Options to Purchase Ordinary Shares | 72,000 | 1.43 | 103.0K | 0 | D | ↗ |
| 2022-11-17 | Binder Hagit | Officer | — | — | Options to Purchase Ordinary Shares | 36,000 | 1.99 | 71.6K | 0 | D | ↗ |
| 2022-04-25 | Russek-Blum Niva | Officer | — | — | Options to Purchase Ordinary Shares | 36,000 | 2.18 | 78.5K | 0 | D | ↗ |
| 2022-03-13 | Tracik Ferenc | Officer | — | — | Options to Purchase Ordinary Shares | 108,000 | 3.51 | 379.1K | 0 | D | ↗ |
| 2022-01-01 | Leuchtenberger Mark | Director | — | — | Options to Purchase Ordinary Shares | 192,000 | 3.51 | 673.9K | 0 | D | ↗ |
| 2021-07-01 | Eisenberg Or | Officer | — | — | Options to Purchase Ordinary Shares | 21,000 | 0.03 | 693.00 | 0 | D | ↗ |
Executive team
Top executives
Shares Outstanding
24.67M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ferenc Tracik | Chief Medical Officer | 447.0K | — |
| Alon Ben-Noon | Co-Founder, Chief Executive Officer & Director | 392.0K | male |
| Or Eisenberg | Chief Financial Officer | 273.0K | male |
| Niva Russek-Blum | Chief Technology Officer | 201.0K | — |
| Keren Pushett | Head of HR | — | female |
| Yael Barak | Vice President of Quality & Compliance | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NRSN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
